PAVmed Q3 2023 Adj EPS $(0.22) Misses $(0.14) Estimate, Sales $783.00K Beat $660.00K Estimate
Portfolio Pulse from vinayak@benzinga.com
PAVmed Inc. (NASDAQ:PAVM) reported Q3 2023 results with an adjusted EPS loss of $(0.22), missing the $(0.14) estimate by 57.14%. Year-over-year, this represents a 46.67% increase in losses from $(0.15) per share. However, sales of $783.00K exceeded estimates of $660.00K by 18.64% and marked a 930.26% increase from $76.00K in the same period last year.
November 14, 2023 | 10:45 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
PAVmed Inc. reported a larger-than-expected Q3 2023 adjusted EPS loss of $(0.22), but surpassed sales estimates with $783.00K in revenue, indicating mixed financial performance.
The missed EPS estimate could negatively impact investor sentiment in the short term, suggesting potential downward pressure on PAVM's stock price. However, the significant sales beat and year-over-year revenue growth may counterbalance the negative EPS impact, leading to a neutral score. The relevance is 100 as the company is the primary subject of the news. The importance is set at 75, considering that earnings reports are critical for investors, but the mixed results may lead to varied interpretations. The confidence level is 85, acknowledging the general market response to earnings reports but also recognizing the potential for unpredictable market reactions.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100